Clinical trials: Neoplasms, Prostate
Prostatic Neoplasms
Study of CP-751,871 in Combination With Docetaxel and Prednisone in Patients With Hormone Insensitive Prostate Cancer (HRPC)
To test the efficacy of CP-751,871 combined with docetaxel and prednisone in the treatment of prostate cancer that is refractory to hormone therapy
- Trial name
- NCT00313781
- Testing
- CP-751,871, docetaxel, prednisone
- Where
- 18 sites in United States, Canada and 4 more
- Volunteers
- 204 people
- Sponsor
- Pfizer
Carcinoma, Non-Small-Cell Lung, Colorectal Cancer
A Study of MDX-1106 in Patients With Selected Refractory or Relapsed Malignancies
To evaluate the safety, tolerability, efficacy, and pharmacokinetics of MDX-1106 when administered to patients with advanced non-small cell lung cancer, colorectal cancer, malignant melanoma, clear cell renal cell cancer or…
- Conditions
- Carcinoma, Non-Small-Cell Lung, Colorectal Cancer, Malignant Melanoma, Renal Cancer
- Trial name
- MDX1106-01 (NCT00441337)
- Testing
- MDX-1106
- Where
- 4 sites in United States
- Volunteers
- 39 people
- Sponsor
- Bristol-Myers Squibb
Prostate Cancer (Post Prostatectomy), Anal Cancer
Assessment of New Radiation Oncology Technologies and Treatments
The Trans Tasman Radiation Oncology Group (TROG) has been commissioned by the Department of Health and Ageing to undertake a project to assess new Radiation Oncology Technology and Treatments.
- Conditions
- Prostate Cancer (Post Prostatectomy), Anal Cancer, Nasopharyngeal Cancer, Intermediate Risk Prostate Cancer
- Trial name
- ANROTAT (NCT01379872)
- Testing
- Non-Interventional Study
- Where
- 15 sites in Australia
- Volunteers
- 138 people
- Sponsor
- Trans Tasman Radiation Oncology Group
Prostatic Neoplasms
A Registry Study to Observe Clinical Outcomes of Participants With High-risk Metastatic Hormone-naïve Prostate Cancer in Japan
The purpose of this registry study is to longitudinally observe clinical outcomes and patient-reported outcomes (PRO) for participants with high-risk metastatic hormone-naive prostate cancer (mHNPC) in the real-world setting in…
- Trial name
- NCT04034095
- Testing
- Androgen-deprivation Therapy (ADT), Bicalutamide, Abiraterone
- Where
- 77 sites in Japan
- Volunteers
- 979 people
- Sponsor
- Janssen Pharmaceutical K.K.
Prostate Cancer
Novel MRI Assessment of Prostate Cancer VALIDATE-PRO
For 50 years the diagnosis of prostate cancer has been with Prostate Specific Antigen (PSA) blood testing and prostate biopsy. However, this approach resulted in over-diagnosis, over-treatment and missed clinical important…
- Trial name
- VALIDATE-PRO (NCT05017181)
- Where
- United Kingdom
- Volunteers
- 234 people
- Sponsor
- University College, London
Breast Neoplasms, Prostatic Neoplasms
Investigating the Impact of Tailored Reports on Anxiety Amongst Cancer Patients and Their Confidants
Objective: To explore the hypothesis that different methods of selecting and printing information for cancer patients could improve emotional support by affecting interaction with others, and so lead to improved psychological…
- Conditions
- Breast Neoplasms, Prostatic Neoplasms, Laryngeal Neoplasms, Cervix Neoplasms
- Trial name
- NCT00127465
- Testing
- Issue of information booklet
- Where
- United Kingdom
- Volunteers
- 400 people
- Sponsor
- University of Plymouth
Colon Cancer, Lung Cancer
Effectiveness of Electronic Health Record-Based Interventions for Improving Follow-Up in Primary Care
Diagnostic delays in ambulatory care are often due to breakdowns of related care processes. Electronic systems can improve follow-up and reduce delays by detecting missed appointments or incomplete procedures so that patients are…
- Conditions
- Colon Cancer, Lung Cancer, Prostate Cancer
- Trial name
- NCT01346839
- Testing
- Contact Intervention
- Where
- 2 sites in United States
- Volunteers
- 1,256 people
- Sponsor
- Baylor College of Medicine
Prostate Cancer
Multi-Center Randomized Clinical Trial Irreversible Electroporation for the Ablation of Localized Prostate Cancer
Multi-centre Randomized Clinical Trial: 106 patients with confirmed unilateral high-volume low risk (Gleason score 3 + 3) or intermediate risk prostate cancer (Gleason score 3 + 4) will undergo an IRE treatment.
- Trial name
- NCT01835977
- Testing
- Irreversible Electroporation (Nanoknife)
- Volunteers
- 106 people
- Sponsor
- Clinical Research Office of the Endourological Society
Prostate Cancer
Prophylactic Vs. Therapeutic Use of Uroxatrol in Men Undergoing Brachytherapy
To asess the efficacy of Uroxatrol, an alpha blocker in men undergoing prostate brachytherapy to treat prostate cancer, and whether the use of Uroxatrol in advance of the brachytherapy is better or not than starting it on the day…
- Trial name
- NCT00201630
- Testing
- Uroxatrol (drug)
- Where
- United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- New York Prostate Institute
Prostate-specific Membrane Antigen, mCRPC or Advanced/Metastatic Solid Tumors
Investigation of PSMA PET/CT as an Imaging Biomarker in Solid Tumors
multi-centre, prospective, diagnostic trial to evaluate the Prostate-Specific Membrane Antigen (PSMA-antigen) over-expression in metastatic castration resistant prostate cancer (mCRPC) and in advanced/metastatic solid tumors…
- Trial name
- BASKET PSMA (NCT03453528)
- Testing
- 68Ga-PSMA
- Where
- Italy
- Volunteers
- 1,225 people
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Prostate Cancer
A First Step Towards Ultra-hypofractionation for Unfavourable Intermediate and High-risk Prostate Cancer
This study aims to make a first step towards ultra-hypofractionation for high-risk prostate cancer by proving the technical feasibility of margin reduction of the seminal vesicles by combining the intra-fraction fiducial tracking…
- Trial name
- UPRATE (NCT05361902)
- Testing
- Adaptive radiotherapy according to UPRATE protocol
- Where
- Netherlands
- Volunteers
- 35 people
- Sponsor
- Erasmus Medical Center
Pharmacokinetics of MDV3100, Castration Resistant Prostate Cancer (CRPC)
Drug-drug Interaction Study With MDV3100 and a Cocktail of Substrates
A drug-drug interaction study to investigate the potential pharmacokinetic interaction between MDV3100 and a cocktail of substrates for pioglitazone (CYP2C8 substrate), S-warfarin (CYP2C9 substrate), omeprazole (CYP2C19…
- Trial name
- NCT01911728
- Testing
- MDV3100, Pioglitazone, Warfarin
- Where
- 2 sites in South Africa
- Volunteers
- 14 people
- Sponsor
- Astellas Pharma Europe B.V.
Prostate Cancer
PROnostic Interest of 18F-FDG PET/CT in Patients With Metastatic Castration-resistant Prostate Cancer (mCPRC) Progressing
The aim of this retrospective study was to assess the prognostic value of parameters extracted from 18FDG PET/CT and 68Ga-PSMA PET in the initial workup and follow-up of patients treated with 177Lu-PSMA in mCRPC.
- Trial name
- PROFLu (NCT06460454)
- Testing
- PET scan of 18F-FDG
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Central Hospital, Nancy, France
Prostate Cancer Metastatic, Castrate Resistant Prostate Cancer
Adjuvant High-intensity Interval Training During Chemotherapy in Metastatic Prostate Cancer Patients
This study aims to examine the use of high-intensity interval training (HIIT) and resistance training on docetaxel chemotherapy tolerability and toxicity in metastatic prostate cancer.
- Conditions
- Prostate Cancer Metastatic, Castrate Resistant Prostate Cancer, Metastatic Prostate Cancer, Metastatic Prostate Adenocarcinoma
- Trial name
- HIIT PCa (NCT05156372)
- Testing
- High Intensity Interval Training
- Where
- United States
- Sponsor
- The University of Texas Health Science Center at San Antonio
Metastatic Castration-resistant Prostate Cancer
177Lu-EB-PSMA617 in Patients With Metastatic Castration-resistant Prostate Cancer
This is an open-label, non-controlled, non-randomized study to assess the safety and measure image-based absorbed dose of 177Lu-EB-PSMA-617 in patients with metastatic castration-resistant prostate cancer (mCRPC) who will undergo…
- Trial name
- NCT03403595
- Testing
- 177Lu-EB-PSMA-617
- Where
- China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Peking Union Medical College Hospital
Diagnostic Imaging
PET/CT (Positron Emission Tomography/Computed Tomography) Imaging for Safety and Tolerability and Diagnostic Performance of BAY1075553 in Patients With Prostate Cancer and Healthy Volunteers
PET/CT imaging study for evaluation of safety and tolerability and diagnostic performance of BAY1075553 in patients with prostate cancer and in healthy volunteers
- Trial name
- NCT01287845
- Testing
- BAY1075553
- Where
- 2 sites in United States, Austria
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Lantheus Biosciences Ltd.
Prostatic Neoplasms
Intrathecal Morphine in Robot-assisted Prostatectomy
This study will investigate the efficacy and safety of intrathecal morphine for the patients undergoing robot-assisted prostatectomy
- Trial name
- RoboITMProst (NCT01991275)
- Testing
- The intravenous patient-controlled analgesia, The intrathecal morphine injection
- Where
- South Korea
- Volunteers
- 30 people
- Sponsor
- Seoul National University Hospital
Prostate Cancer
Phase 1/2 Clinical Study of Lutetium Lu 177 JH020002 Injection in Patients With Advanced Prostate Cancer
The study is being conducted to evaluate the safety, tolerability, pharmacokinetics, radiation dosimetry, and preliminary efficacy of Lutetium Lu 177 JH020002 Injection in adult patients with advanced prostate cancer.
- Trial name
- NCT06139575
- Testing
- Lutetium Lu 177 JH020002 Injection
- Where
- 13 sites in China
- Volunteers
- 90 people
- Sponsor
- Bivision Pharmaceuticals, Inc.
Prostate Cancer
AGN-Cogni.Q Acute Dose Safety and Pharmacokinetics Dose-Response in Prostate Cancer Patients
This study is to obtain acute dose safety and pharmacokinetics/pharmacodynamics (PK/PD) data in a dose-response trial in prostate cancer patients.
- Trial name
- NCT05375539
- Testing
- AGN-Cogni.Q
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Milton S. Hershey Medical Center
Prostate Cancer
Radiotherapy to the Prostate and Dominant Intra-Prostatic Lesion (DIL)
The purpose of the study is to find out the feasibility and effects of ultra-hypofractionated radiotherapy to the prostate and dominant lesion as definitive treatment for intermediate risk prostrate cancer.
- Trial name
- NCT03269422
- Testing
- MR-based image-guided, intensity-modulated radiotherapy
- Where
- 7 sites in United States
- Volunteers
- 35 people
- Sponsor
- Memorial Sloan Kettering Cancer Center